SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research Company is currently trading at Rs. 180.40, up by 0.70 points or 0.39% from its previous closing of Rs. 179.70 on the BSE.

The scrip opened at Rs. 179.30 and has touched a high and low of Rs. 185.25 and Rs. 176.50 respectively. So far 344044 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.25 on 02-Jun-2025 and a 52 week low of Rs. 108.20 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 189.65 and Rs. 137.00 respectively. The current market cap of the company is Rs. 5854.37 crore.

The promoters holding in the company stood at 65.67%, while Institutions and Non-Institutions held 2.91% and 31.42% respectively.

Sun Pharma Advanced Research Company’s (SPARC) licensing partner -- Ocuvex Therapeutics Inc. has received a Complete Response Letter (CRL) from the United States Food and Drug Administration (USFDA) for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility. The USFDA did not raise any other issues with the PDP-716 NDA.

Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.

Sun Pharma Adv. Res Share Price

242.05 2.65 (1.11%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 440.40
Indegene 517.40
CMS Info Systems 294.40
JITF Infralogistics 299.95
Sagility 39.83
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: